A Report by the American Academy of Ophthalmology
Ophthalmic Technology Assessment Committee Refractive Management/Intervention Panel:
David Huang, MD, PhD; Steven C. Schallhorn, MD; Alan Sugar, MD, MS; Ayad A. Farjo, MD; Parag A. Majmudar, MD; William B. Trattler, MD; David J. Tanzer, MD
Published in Ophthalmology, November 2009, Vol. 116, 2244-2258
- Evidence-based summary of safety and outcomes for pIOL implantation
- UCVA ≥20/40 in 84% in FDA trials of iris-fixated pIOLs
- UCVA ≥20/40 in 81% in FDA trials of posterior chamber pIOLs
- Reported complications and safety concerns:
- Endothelial cell loss
- Cataract formation
- Secondary glaucoma
- Iris atrophy
- Traumatic dislocation
- Evidence supports phakic IOL implantation as a safe and effective treatment for myopia and astigmatism
